

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	HMC Capital Limited (ASX: HMC)
<b>ABN</b>	94 138 990 593

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Christopher Roberts
<b>Date of last notice</b>	11 April 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ul style="list-style-type: none"><li>Romaxis Pty Ltd (ACN 126 199 924) as trustee for &lt;Roblis Super Fund A/C&gt; (of which Christopher Roberts is a beneficiary) (<b>Romaxis</b>)</li><li>Acemed Pty Ltd (ACN 078 477 193) as trustee for &lt;MAXIS A/C&gt; (of which Christopher Roberts is a beneficiary) (<b>Acemed</b>)</li></ul>
<b>Date of change</b>	20 August 2025

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held prior to change</b>	<b>Direct interest:</b> <ul style="list-style-type: none"> <li>714 fully paid ordinary shares</li> <li>3,952 rights to acquire fully paid ordinary shares</li> </ul> <b>Indirect interest:</b> <ul style="list-style-type: none"> <li>Romaxis – 150,000 fully paid ordinary shares</li> <li>Acemed – 150,000 fully paid ordinary shares and 10,000 options (exercise price of \$7, expiry 30/11/25)</li> </ul>
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	3,952 fully paid ordinary shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<b>Direct interest:</b> <ul style="list-style-type: none"> <li>4,666 fully paid ordinary shares</li> </ul> <b>Indirect interest:</b> <ul style="list-style-type: none"> <li>Romaxis – 150,000 fully paid ordinary shares</li> <li>Acemed – 150,000 fully paid ordinary shares and 10,000 options (exercise price of \$7, expiry 30/11/25)</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Tranche 2 of 2 of the exercise of rights to acquire fully paid ordinary shares in lieu of board fees for FY25 under the Non-Executive Director Equity Plan.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	Not applicable
<b>Nature of interest</b>	Not applicable

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Name of registered holder (if issued securities)</b>	Not applicable
<b>Date of change</b>	Not applicable
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	Not applicable
<b>Interest acquired</b>	Not applicable
<b>Interest disposed</b>	Not applicable
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Not applicable
<b>Interest after change</b>	Not applicable

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable
<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable

---

<sup>+</sup> See chapter 19 for defined terms.